US FDA Warning Letters for inadequate Batch Records

The U.S. Food and Drug Administration (FDA) recently posted Warning Letters criticising incomplete batch production and control records.

For example, at a company in Spain, the inspector found

  • white-out correction liquid
  • unintelligible data
  • missing information such as test results and the date of approval
  • over written or crossed-out entries with "no signature, date, or explanation"
  • no proof that a second person has reviewed record "for accuracy, completeness, and compliance with established standards"

Furthermore, FDA criticised a missing identity and strength testing, an inadequate stability testing programme and - of course - "Data Integrity Remediation".

As a conclusion, FDA stated that the company's "quality systems are inadequate" and placed the firm on Import Alert.

At a site in California (USA) an investigator found that the firm was not performing final reviews of batches manufactured by a third party manufacturer before disposition. Determining the suitability of each batch for release is an essential component of your QU responsibility.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.